Format

Send to

Choose Destination
Memo. 2017;10(4):240-243. doi: 10.1007/s12254-017-0366-9. Epub 2017 Nov 13.

ASCO-update: gastrointestinal tumors.

Author information

1
IIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute (SCRI), Paracelsus Medical University, Muellner Hauptstraße 48, 5020 Salzburg, Austria.

Abstract

A multitude of new molecular and immunologic insights into gastrointestinal tumors have been presented at the ASCO meeting 2017; however, we have focused our update on practice-changing phase 3 trials and tried to set them into clinical perspective. Furthermore, we will elaborate on updated data on immunotherapeutics in gastroesophageal cancers, since drug approvals may be anticipated before convening for the next meeting in 2018.

KEYWORDS:

Biliary tract cancer; Cololrectal cancer; Gastric cancer; Immune checkpoint inhibitor

Conflict of interest statement

L. Weiss, F. Huemer, and R. Greil declare that they have no competing interests.

Publication type

Publication type

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center